Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SRZN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| SZN-8141 for Injection | Diabetic Macular Edema (DME) | Phase 1 · NCT07817121 | Not yet recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SRZN had $100.4M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $220.3M pro forma, before operating spending after that date:
It burns about $6.1M/quarter from operations, an estimated runway of 108 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SRZN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| COLUMN GROUP III GP, LP 10% owner · +431,034 options |
Insider | 3,813,501 | 20.01% | 2026-10-20 |
| Tim Kutzkey Director, 10% owner · +436,584 options Includes shares also reported by COLUMN GROUP III GP, LP, counted once |
Insider | 3,813,501 | 20.01% | 2026-11-06 |
| Boxer Capital Management, LLC | Institution (13G, 5%+) | 1,360,683 | 7.14% | 2026-09-30 |
| Venrock Healthcare Capital Partners III, | 5%+ holder (13G) | 1,205,000 | 6.32% | 2026-03-31 |
| Chen Yu | 5%+ holder (13G) | 1,148,101 | 6.02% | 2026-07-22 |
| 5AM Partners VII, LLC | 5%+ holder (13G) | 968,750 | 5.08% | 2026-06-30 |
| Commodore Capital LP | Institution (13G, 5%+) | 885,000 | 4.64% | 2026-09-24 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 871,731 | 4.57% | 2025-12-31 |
| BALYASNY ASSET MANAGEMENT L.P. | Institution (13G, 5%+) | 659,111 | 3.46% | 2026-09-30 |
| Point72 Asset Management, L.P. | 5%+ holder (13G) | 615,957 | 3.23% | 2026-04-22 |
| StemPoint Capital LP | Institution (13G, 5%+) | 602,798 | 3.16% | 2026-06-30 |
| TCG Crossover GP II, LLC 10% owner |
Insider | 574,047 | 3.01% | 2026-07-22 |
Share count 19,061,662 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SRZN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →